Get to know our clinical trials
Ensayo clínico de tratamientos basados en daratumumab en participantes con amiloidosis de cadenas ligeras de amiloide
EL PROPÓSITO DE ESTE ESTUDIO ES COMPARAR LA SEGURIDAD DE DIFERENTES PAUTAS DE TRATAMIENTO CON DARATUMUMAB ASOCIADO A BORTEZOMIB, CICLOFOSFAMIDA Y DEXAMETASONA (D-VCD) Y TAMBIÉN INVESTIGAR LAS CONCENTRACIONES DEL MEDICAMENTO DEL ESTUDIO, DARATUMUMAB, EN LA SANGRE DE PACIENTES, DE ORÍGENES DIVERSOS, CON AMILOIDOSIS AL RECIÉN DIAGNOSTICADA.
Technical Summary
- ESTUDIO DE FASE 2, MULTICOHORTE, DE TRATAMIENTOS BASADOS EN DARATUMUMAB EN PARTICIPANTES CON AMILOIDOSIS DE CADENAS LIGERAS DE AMILOIDE (AL). INMUNOTERAPIA
- Code EudraCT: 2021-002639-48
- Protocol number: 54767414AMY2009
- Promoter: Janssen Research & Development
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.